TechSeeker Profile

Curis Inc (AKA: Creative Biomolecules Inc)
Profile last edited on: 10/9/2013

Drug development company that focuses on regulatory pathways that control repair and regeneration.
TS Type
Small Corp
Status
Merger
Year Founded
1981
Last Involved Year
2002

Key People / Management

  Carmen Pepicelli -- Executive Director, Program and Alliance Management

Location Information

4 Maguire Road
Lexington, MA 02138
   (617) 503-6500
   www.curis.com

Public Profile

Formerly knowly known as Creative BioMolecules, during 2000, Creative Biomolecules, Ontogeny, Inc. and Reprogenesis, Inc. merged to form Curis, Inc. The new Company's core technologies are based on its understanding of the role that morphogenic proteins play in human biology. These proteins are involved in the initiation and regulation of the cellular events responsible for the formation of human tissues and organs. The Company has product candidates in development for several applications including orthopaedic and dental reconstruction, treatment of kidney disease, and treatment of stroke and other neurological disorders. Through its efforts to patent and license its technology, the Company has a strong intellectual property position covering morphogenic proteins as therapies. The Company's lead product candidate, the OP-1 bone graft device, is in the final stages of development and commercialization.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
62
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : CRIS
Received SBIR $$
Yes

Techseeker firm in the news

There are no news available.